Femasys Inc.(FEMY)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Femasys faces a precarious financial outlook characterized by a $145.0M accumulated deficit and a reliance on external capital to fund its clinical pipeline.
• While the company maintains a gross margin profile often exceeding 65%, the inability to scale revenue consistently—evidenced by a 30.9% contraction in 2024Q2—suggests significant execution risk.
• Investors should monitor the company's $5.4M cash position, which appears insufficient to support long-term R&D requirements without further dilutive financing.